Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05081609
Title IL Believe: A Study of TransCon IL-2 beta/gamma Alone or in Combination With Pembrolizumab or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (IL Believe)
Acronym IL Believe
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Ascendis Pharma Oncology Division A/S
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | ITA | ESP | CAN | BEL | AUS


No variant requirements are available.